Quarterly ResultAug 11, 2026, 04:23 PM
LENZ Therapeutics Reports First VIZZ® Product Sales of $1.7M
AI Summary
LENZ Therapeutics reported its first product sales of VIZZ® following FDA approval in July 2025, with Q2 2026 product sales reaching $1.736 million and total revenue of $5.486 million. Despite this new revenue stream, the company posted a net loss of $31.918 million for the quarter, increasing its accumulated deficit to $300.5 million. LENZ maintains a strong liquidity position with $220.0 million in cash, cash equivalents, and marketable securities, which it expects to be sufficient for at least the next 12 months.
Key Highlights
- Total revenue for Q2 2026 was $5.486 million, up from $5.000 million in Q2 2025.
- Product sales, net, for Q2 2026 were $1.736 million, compared to $0 in Q2 2025.
- Net loss for Q2 2026 was $31.918 million, an increase from $14.912 million in Q2 2025.
- Accumulated deficit reached $300.5 million as of June 30, 2026.
- Cash, cash equivalents, and marketable securities totaled $220.0 million as of June 30, 2026.
- Net cash used in operating activities for the six months ended June 30, 2026, was $72.295 million.
- Selling, general and administrative expenses increased to $39.378 million in Q2 2026 from $12.796 million in Q2 2025.
Price Impact
More from LENZ